In agreement with the effects observed in the plasma and neutrophils of severe COVID‐19 patients (Figure 2), similar results were observed in which DNase‐I pMNSs induced a drastic reduction in the levels of peritoneal neutrophils, NETs, eDNA, NE activity, and MPO activity compared to those in the control group (PBS treatment) and free DNase‐I group. The gene discussed is MPO; the disease is COVID-19.